NasdaqCM - Delayed Quote USD
Acasti Pharma Inc. (ACST)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:09 PM EDT
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
--
--
--
--
196.0000
--
Cost of Revenue
--
--
--
--
76.0000
--
Gross Profit
--
--
--
--
120.0000
--
Operating Expense
13,361.0000
11,367.0000
18,247.0000
15,340.0000
10,836.0000
--
Operating Income
-13,361.0000
-11,367.0000
-18,247.0000
-15,340.0000
-10,716.0000
--
Net Non Operating Interest Income Expense
1,012.0000
911.0000
246.0000
77.0000
-157.0000
--
Other Income Expense
-1,365.0000
-4,229.0000
-33,970.0000
4,796.0000
-8,805.0000
--
Pretax Income
-13,714.0000
-14,685.0000
-51,971.0000
-10,467.0000
-19,678.0000
--
Tax Provision
-2,267.0000
-1,832.0000
-9,542.0000
-648.0000
--
--
Net Income Common Stockholders
-11,447.0000
-12,853.0000
-42,429.0000
-9,819.0000
-19,678.0000
--
Diluted NI Available to Com Stockholders
-11,447.0000
-12,853.0000
-42,429.0000
-9,819.0000
-19,678.0000
--
Basic EPS
-1.43
-1.73
-5.71
-1.62
-7.98
--
Diluted EPS
-1.43
-1.73
-5.71
-1.62
-7.98
--
Basic Average Shares
8,309.1660
7,435.9130
7,435.4720
6,140.2930
2,471.3720
--
Diluted Average Shares
8,309.1660
7,435.9130
7,435.4720
6,140.2930
2,471.3720
--
Total Operating Income as Reported
-13,361.0000
-12,852.0000
-52,155.0000
-15,589.0000
-16,419.0000
--
Total Expenses
13,361.0000
11,367.0000
18,247.0000
15,340.0000
10,912.0000
--
Net Income from Continuing & Discontinued Operation
-11,447.0000
-12,853.0000
-42,429.0000
-9,819.0000
-19,678.0000
--
Normalized Income
-10,307.6420
-9,151.5811
-14,695.9733
-14,180.1857
-10,873.0000
--
Interest Income
1,012.0000
911.0000
246.0000
77.0000
107.0000
--
Interest Expense
--
--
--
--
--
247.0000
Net Interest Income
1,012.0000
911.0000
246.0000
77.0000
-157.0000
--
EBIT
-13,361.0000
-11,367.0000
-18,247.0000
-15,340.0000
-10,716.0000
--
EBITDA
-13,323.0000
-11,327.0000
-18,123.0000
-15,340.0000
-9,792.0000
--
Reconciled Cost of Revenue
--
--
--
--
76.0000
--
Reconciled Depreciation
5.0000
11.0000
124.0000
--
924.0000
--
Net Income from Continuing Operation Net Minority Interest
-11,447.0000
-12,853.0000
-42,429.0000
-9,819.0000
-19,678.0000
--
Total Unusual Items Excluding Goodwill
-1,365.0000
-4,229.0000
-33,970.0000
4,649.0000
-8,805.0000
--
Total Unusual Items
-1,365.0000
-4,229.0000
-33,970.0000
4,649.0000
-8,805.0000
--
Normalized EBITDA
-11,958.0000
-7,098.0000
15,847.0000
-19,989.0000
-987.0000
--
Tax Rate for Calcs
0.0002
0.0001
0.0002
0.0001
--
--
Tax Effect of Unusual Items
-225.6420
-527.5811
-6,236.9733
287.8143
--
--
3/31/2020 - 2/7/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CYCN Cyclerion Therapeutics, Inc.
2.5000
-5.66%
OGEN Oragenics, Inc.
0.3260
+0.34%
ENTX Entera Bio Ltd.
1.8500
+1.09%
VYNE VYNE Therapeutics Inc.
2.2150
+1.14%
ITRM Iterum Therapeutics plc
1.1700
+7.34%
ADXS Ayala Pharmaceuticals, Inc.
0.0270
0.00%
IBIO iBio, Inc.
2.8700
+0.70%
CARA Cara Therapeutics, Inc.
0.2651
-0.64%
SPRB Spruce Biosciences, Inc.
0.5190
+1.76%
KTTA Pasithea Therapeutics Corp.
4.3200
+8.27%